Tesamorelin (20 mg Vial) Dosage Protocol

Supply calculations below use the displayed 2 mg once-daily research amount for 8, 12, and 16 weeks.

• Peptide vials (Tesamorelin, 20 mg each):
  • 8 weeks: 6 vials (112 mg total)
  • 12 weeks: 9 vials (168 mg total)
  • 16 weeks: 12 vials (224 mg total)
• U-100 insulin syringes:
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic water (10 mL bottles):
  • Use 3.0 mL per vial.
  • 8 weeks: 18 mL → 2 bottles
  • 12 weeks: 27 mL → 3 bottles
  • 16 weeks: 36 mL → 4 bottles
• Alcohol swabs:
  • Two per administration.
  • 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
  • 16 weeks: 224 swabs — 3 boxes required (100 swabs each)

Sharps safety: Place used syringes directly into an appropriate sharps container and follow local disposal requirements.

Tesamorelin 20 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

• Reconstitute: Add 3.0 mL bacteriostatic water per 20 mg vial → ~6.67 mg/mL concentration.
• Phase 3 research amount: 2 mg (2000 mcg) once daily by subcutaneous injection for 26 weeks.^[3]
• Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); reconstituted: refrigerate and follow the exact formulation’s validated use-by period.

Tesamorelin is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH)^[1]. It stimulates endogenous growth hormone release and raises IGF-1 levels, leading to enhanced lipolysis and metabolic benefits^[2]. Tesamorelin is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy and is studied for metabolic disorders and aging research^[3][4].

A 20 mg vial describes total nominal vial content. It does not replace the amount assigned to one administration. With the page’s unchanged 3.0 mL final volume, the concentration is approximately 6.67 mg/mL. The cited phase 3 amount of 2 mg therefore occupies 0.30 mL, or 30 U-100 syringe units.^[3]

This strength-specific peptide dosage calculator is a reconstitution-math aid for the same family schedule, not a separate dosing protocol or a prescribing tool.

Twenty milligrams divided by the 2 mg research amount equals 10 nominal 2 mg calculations. At 6.67 mg/mL, each calculation is 0.30 mL. The result is mathematical vial yield; it does not establish sterility, recovery, potency, or a discard date after reconstitution.

The supplier listing documents the 20 mg product identity and destination, not the clinical schedule.^[11]

Record the prepared concentration as Tesamorelin 6.67 mg/mL, along with the preparation date, vial identifier, diluent lot, 30-unit marking, 0.30 mL volume, 2 mg mass, study day, and documented injection site. Follow the exact product documentation for storage and discard timing.

This calculator-style tesamorelin 20 mg dosage page uses the concentration already established in the primary chart. Dividing 20 mg by 3.0 mL gives approximately 6.67 mg/mL. A U-100 insulin syringe is marked by volume: one unit equals 0.01 mL. At this concentration, each unit represents about 66.7 mcg.

• 1 mg: 15 units (0.15 mL).
• 2 mg: 30 units (0.30 mL).
• Full vial: 20 mg in 3.0 mL.

For this dosage calculator, 3.0 mL of bacteriostatic water is the fixed final-volume input. The calculation moves in both directions: 30 units multiplied by 0.01 mL equals 0.30 mL, and 0.30 mL multiplied by 6.67 mg/mL is approximately a 2 mg tesamorelin dose. U-100 syringe units are volume markings, not peptide international units.

The schedule shown in Cards 01–03 remains unchanged: 2 mg by subcutaneous injection once daily for 26 weeks. The pooled phase 3 analysis used that amount and duration and reported extension observations through 52 weeks.^[3] The two phase 3 trials and their extensions define the research protocol summarized here. A separate randomized trial and extension likewise evaluated 2 mg each day and found that visceral-fat improvements were maintained in participants who continued daily tesamorelin, while the earlier change was lost after switching to placebo.^[12]

A 20 mg vial changes the reconstitution math, draw volume, syringe marking, nominal number of calculations, and supply counts. It does not create a loading phase, escalation, taper, or different frequency.

At the displayed 2 mg research amount, one 20 mg vial has a nominal yield of 10 administrations. The supplies card applies that arithmetic to 8, 12, and 16 weeks and rounds vial quantities upward so a partial vial is never counted as a complete one. Daily administration also means one new syringe and two alcohol swabs per study day.

Bacteriostatic-water totals use 3.0 mL per vial. These planning values are tied to this page’s inputs; changing the final volume or displayed research amount requires recalculating concentration, U-100 units, mL, vial counts, water totals, and nominal yield together.

Nominal yield should not be read as proof that every theoretical administration can be recovered from a vial. Real-world preparation can involve dead space, handling loss, and product-specific stability limits.

EGRIFTA SV is a specific FDA-approved 2 mg single-dose vial supplied with sterile water. The FDA label describes a 1.4 mg once-daily dose, a 0.5 mL reconstitution volume, and immediate use after preparation.^[7] Tesamorelin is a prescription drug in that approved-product context. Those directions are formulation-specific and do not transfer to a separately supplied 20 mg vial.

This page instead translates the 2 mg amount evaluated in phase 3 research into a 20 mg vial calculation based on a 3.0 mL final volume. It does not substitute the vial strength, diluent, labeled dose, injection volume, storage period, or discard instructions of one formulation for another.

In a randomized trial of 412 adults with HIV and abdominal fat accumulation, daily subcutaneous tesamorelin for 26 weeks reduced visceral adipose tissue by 15.2%, while the placebo group increased by 5.0%. Triglycerides and the total-cholesterol-to-HDL ratio also improved in the tesamorelin group.^[10]

The pooled phase 3 analysis reported a reduction in visceral adipose tissue and maintenance of that reduction during continued treatment through the 52-week extension.^[3] A responder analysis associated an 8% or greater visceral-fat reduction with selected changes in triglycerides, adiponectin, and glucose-homeostasis measures.^[14]

These outcomes apply to the defined clinical populations and study designs. They do not make a 20 mg vial a general weight-loss product, and the current EGRIFTA SV label states that it is not indicated for weight-loss management.^[7]

A six-month randomized study in antiretroviral-treated adults with HIV and abdominal fat accumulation used 2 mg daily and reported reductions in visceral and liver fat compared with placebo. An early fasting-glucose difference was not sustained as a significant between-group difference at six months.^[13]

A 12-month trial in people with HIV and nonalcoholic fatty liver disease reported a greater reduction in hepatic fat fraction with tesamorelin than placebo.^[15] A later analysis among participants using integrase inhibitors reported reductions in visceral and hepatic fat without evidence of worsened glycemic control in that subgroup.^[16]

Another randomized study evaluated 1 mg and 2 mg amounts in people with type 2 diabetes for 12 weeks and did not find a significant between-group change in overall glycemic control.^[4] Population, duration, comparator, outcome definition, and formulation therefore matter when interpreting tesamorelin research.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It acts at receptors on pituitary somatotroph cells, stimulates the pulsatile release of growth hormone, and can increase circulating IGF-1.^[1][2] This pathway differs from administering growth hormone directly.

The mechanism helps explain why clinical sources discuss IGF-1, glucose, fluid retention, and injection-site monitoring. Exploratory cognitive findings have also been reported in older adults, but they do not establish a tesamorelin dosage for cognitive enhancement, healthy aging, or use outside the studied populations.^[5]

Clinical and prescribing sources describe subcutaneous injection in the abdomen with rotation of injection sites.^[6][7] General subcutaneous technique includes cleaning the vial stopper and selected skin site, allowing the alcohol swab to dry, using a new sterile syringe and needle, and following the governing procedure for needle angle and administration.^[9] Product-specific reconstitution instructions and discard timing still control for the exact formulation being handled.

• Verify the 30-unit U-100 marking and its 0.30 mL equivalent before recording the 2 mg calculation.
• Do not confuse U-100 volume markings with peptide IU.
• Rotate and document injection sites rather than repeatedly using one location.
• Place each used needle and syringe directly into an appropriate sharps container.

Clinical and labeling sources identify injection-site reactions, fluid retention, joint or muscle symptoms, carpal-tunnel symptoms, hypersensitivity, elevated IGF-1, and glucose intolerance or diabetes risk as relevant considerations.^[1][7][8] The label also lists contraindications that include active malignancy, pregnancy, disruption of the hypothalamic-pituitary axis, and hypersensitivity to the labeled formulation.^[7]

Adverse-event frequencies and monitoring procedures belong to their cited population, study design, and product formulation. They are not a safety guarantee for a separately supplied vial or another research setting.

How much bacteriostatic water does this 20 mg chart use?

The chart uses 3.0 mL, producing a concentration of approximately 6.67 mg/mL. This is a page-specific calculation input, not a universal direction for every tesamorelin formulation.

How many U-100 syringe units equal 2 mg?

At 6.67 mg/mL, 2 mg occupies 0.30 mL, which is 30 units on a U-100 insulin syringe.

How many 2 mg calculations are in a 20 mg vial?

Ten nominal calculations. That result is mass arithmetic only and does not determine sterility, recoverable volume, storage life, or permission to retain a prepared vial.

Does a 20 mg vial change the phase 3 dosing schedule?

No. The accepted family schedule remains 2 mg once daily for 26 weeks, with extension evidence through 52 weeks.^[3] Vial strength changes the measurement and supply arithmetic, not the study-defined amount or frequency.

Is this 20 mg vial the same as EGRFFTASV?

No. EGRIFTA SV” is a different 2 mg single-dose formulation with its own supplied diluent, labeled 1.4 mg dose, preparation instructions, and immediate-use requirement.^[7]

Can the 30-unit calculation be used with a different water volume?

No. The 30-unit result is specific to 20 mg in 3.0 mL. A different final volume changes concentration, mcg per unit, syringe units, and mL together.

This tesamorelin 20 mg dosage page translates a published research schedule into strength-specific concentration, U-100 syringe units, mL, nominal vial yield, and supply planning for research use. It does not establish an individualized regimen, validate a product-specific storage period, or constitute medical advice.

• 1
  Tesamorelin – LiverTox: Clinical and Research Information on Drug-Induced Liver Injury — National Institute of Diabetes and Digestive and Kidney Diseases (2018)

  View Source
• 2
  Tesamorelin (Subcutaneous Route) – Drug Information — Mayo Clinic / IBM Merative

  View Source
• 3
  Effects of Tesamorelin in HIV-Infected Patients With Excess Abdominal Fat: Pooled Phase 3 Analysis — Journal of Clinical Endocrinology and Metabolism (2010)

  View Source
• 4
  Safety and Metabolic Effects of Tesamorelin in Patients With Type 2 Diabetes — PLOS ONE (2017)

  View Source
• 5
  Tesamorelin Can Improve Cognitive Function — Nature Reviews Endocrinology research highlight (2012)

  View Source
• 6
  Tesamorelin Injection — MedlinePlus Drug Information

  View Source
• 7
  EGRIFTA SV Prescribing Information — U.S. Food and Drug Administration (2024)

  View Source
• 8
  Tesamorelin: Uses, Dosage, Side Effects, and Warnings — Drugs.com

  View Source
• 9
  Administration of Parenteral Medications — Open RN Nursing Skills, NCBI Bookshelf (2023)

  View Source
• 10
  Metabolic Effects of a Growth Hormone-Releasing Factor in Patients With HIV — New England Journal of Medicine (2007)

  View Source
• 11
  Pure Lab Peptides Tesamorelin 20 mg Product Page — product identity and supplier information

  View Source
• 12
  Effects of Tesamorelin in HIV-Infected Patients With Abdominal Fat Accumulation: Randomized Trial and Safety Extension — Journal of Acquired Immune Deficiency Syndromes (2010)

  View Source
• 13
  Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients — JAMA (2014)

  View Source
• 14
  Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile — Clinical Infectious Diseases (2012)

  View Source
• 15
  Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease in HIV — Lancet HIV (2019)

  View Source
• 16
  Efficacy and Safety of Tesamorelin in People With HIV on Integrase Inhibitors — AIDS (2024)

  View Source